New antibody combo could shield kids from rabies after bites

NCT ID NCT07327307

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 232 children under 18 who received a new antibody injection (zamerovimab and mazorelvimab) plus the rabies vaccine after a severe animal bite. Researchers track whether the children stay rabies-free for up to one year. The goal is to see if this combination prevents rabies effectively in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zamerovimab and Mazorelvimab injection (antibodies) plus rabies vaccine
What this could lead to
If successful, this could confirm a new antibody treatment that, combined with the vaccine, prevents rabies after severe bites in children.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Rabies is rare, so proving effectiveness is challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES POST-EXPOSURE PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Nanhua Hospital, University of South China

    RECRUITING

    Hengyang, Hunan, China

  • Hunan Provincial People's Hospital

    RECRUITING

    Changsha, Hunan, China

  • Jiangxi Provincial Chest Hospital

    RECRUITING

    Nanchang, Jiangxi, China

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Shenzhen second people's hospital

    RECRUITING

    Shenzhen, Guangdong, China

  • The University of Hong Kong - Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.